Evidence map›Paper›PMID 27856957›Full record

ArticleMolecular cancer research : MCR2017

Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis.

Denise K Reaves, Katherine A Hoadley, Katerina D Fagan-Solis, Dereje D Jima, Michael Bereman, Lynnelle Thorpe, Jyla Hicks, David McDonald, Melissa A Troester, Charles M Perou and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. LSR Promotes Cell Proliferation and Invasion in Lung Cancer.Computational and mathematical methods in medicine · 2021
    Article
  10. Leptin Downregulates Angulin-1 in Active Crohn's Disease via STAT3.International journal of molecular sciences · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Interaction ofToxins · 2018
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Denise K ReavesDepartment of Biology, North Carolina Central University, Durham, North Carolina.
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Katerina D Fagan-SolisDepartment of Biology, North Carolina Central University, Durham, North Carolina.
Dereje D JimaCenter for Human Health and the Environment, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina.
Michael BeremanCenter for Human Health and the Environment, Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina.
Lynnelle ThorpeDepartment of Biology, North Carolina Central University, Durham, North Carolina.
Jyla HicksDepartment of Biology, North Carolina Central University, Durham, North Carolina.
David McDonaldDepartment of Biology, North Carolina Central University, Durham, North Carolina.
Melissa A TroesterLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Jodie M FlemingDepartment of Biology, North Carolina Central University, Durham, North Carolina. jodie.fleming@nccu.edu.
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHARLES M PEROU · 1992 to 2026
$59.3M
Translational Research Support CoreP30ES025128 · NIEHS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI Sue Fenton · 2015 to 2026
$18.3M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156735 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI RICHARDSON, MICHELER RICARDO · 2010 to 2021
$13.0M
Targeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156733 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SANCAR, GWENDOLYN B · 2010 to 2020
$9.7M
Development of a novel targeted-therapy for treatment of basal-like breast cancerSC2CA176585 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI FLEMING, JODIE MICHELLE · 2012 to 2014
$374k
HGF signaling in African-American and Basal-like Breast CancerR21CA175783 · NCI · NORTH CAROLINA CENTRAL UNIVERSITY · PI FLEMING, JODIE MICHELLE, TROESTER, MELISSA A. · 2013 to 2014
$348k
Howard Hughes Medical Institute 52007553NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R21 CA175783NCI NIH HHS SC2 CA176585NCI NIH HHS U54 CA156733NCI NIH HHS U54 CA156735NIEHS NIH HHS P30 ES025128
6 · The paper itself

Abstract

Lipolysis-stimulated lipoprotein receptor (LSR) has been found in the plasma membrane and is believed to function in lipoprotein endocytosis and tight junctions. Given the impact of cellular metabolism and junction signaling pathways on tumor phenotypes and patient outcome, it is important to understand how LSR cellular localization mediates its functions. We conducted localization studies, evaluated DNA binding, and examined the effects of nuclear LSR in cells, xenografts, and clinical specimens. We found LSR within the membrane, cytoplasm, and the nucleus of breast cancer cells representing multiple intrinsic subtypes. Chromatin immunoprecipitation (ChIP) showed direct binding of LSR to DNA, and sequence analysis identified putative functional motifs and post-translational modifications of the LSR protein. While neither overexpression of transcript variants, nor pharmacologic manipulation of post-translational modification significantly altered localization, inhibition of nuclear export enhanced nuclear localization, suggesting a mechanism for nuclear retention. Coimmunoprecipitation and proximal ligation assays indicated LSR-pericentrin interactions, presenting potential mechanisms for nuclear-localized LSR. The clinical significance of LSR was evaluated using data from over 1,100 primary breast tumors, which showed high LSR levels in basal-like tumors and tumors from African-Americans. In tumors histosections, nuclear localization was significantly associated with poor outcomes. Finally, in vivo xenograft studies revealed that basal-like breast cancer cells that overexpress LSR exhibited both membrane and nuclear localization, and developed tumors with 100% penetrance, while control cells lacking LSR developed no tumors. These results show that nuclear LSR alters gene expression and may promote aggressive cancer phenotypes. IMPLICATIONS: LSR functions in the promotion of aggressive breast cancer phenotypes and poor patient outcome via differential subcellular localization to alter cell signaling, bioenergetics, and gene expression. Mol Cancer Res; 15(2); 165-78. ©2016 AACR.

Indexed as

AnimalsBreast NeoplasmsCarcinogenesisCell Transformation, NeoplasticFemaleHeterograftsHumansMiceReceptors, LDLlipolysis-stimulated receptorReceptors, LDL

Identifiers

PMID27856957
PMCPMC5290211
OpenAlexW2554832514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.